$1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021.
It will also cover the cost of running a large Phase III trial - the final stage of human testing, which could begin as early as October.Scientists are racing to create a coronavirus vaccine that can halt the pandemic in its tracks. Here are the top 3 candidates aiming to be ready this fall. The Gaithersburg, Maryland-based company is somewhat of a dark horse in the race for a coronavirus vaccine. The company was not on the list of vaccine finalists for Warp Speed reported by the New York Times that included Moderna, AstraZeneca, Pfizer Inc., J&J, and Merck & Co.Dozens of drugmakers are racing to develop coronavirus vaccines. Here's how they see 2020 playing out and when the first vaccines might be available.
Currently, Novavax makes its adjuvant in Sweden. The company is building up U.S. manufacturing capacity for its adjuvant "so that we can make upwards of a billion doses of adjuvant in the United States," he said.How 13 top drugmakers are sprinting to develop a coronavirus vaccine or treatment that can halt this pandemic
Novavax Fates and CDC Genocide CrimesAgainstHumanity CrimesAgainstChildren DrBright H1N1 SwineFlu Vaccine
My knee jerk is to roll my eyes. But we should be giving money to vaccine developers... it’s a drop in the bucket compared to the impact on our economy. Will be really interested to see the reporting.
Lemme guess he owns part of Novavax